Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 2, keine Gesamtzahl für „Corlentor“
Suchtreffer
Begriffe & Kennungen
Corlentor · 4.5 · Pharmacokinetic interactions
Eintrag öffnenCorlentor · 4.5 · Potassium-depleting diuretics (thiazide diuretics and loop diuretics) Hypokalemia can increase the risk of arr
Eintrag öffnenCorlentor · 4.5 · Potent CYP3A4 inhibitors The concomitant use of potent CYP3A4 inhibitors such as azole antifungals (ketoconazo
Eintrag öffnenCorlentor · 4.5 · QT prolonging medicinal products - Cardiovascular QT prolonging medicinal products (e.g. quinidine, disopyrami
Eintrag öffnenCorlentor · 4.5 · The concomitant use of ivabradine with other moderate CYP3A4 inhibitors (e.g. fluconazole) may be considered a
Eintrag öffnenCorlentor · 4.6 Fertility, pregnancy and lactation · 1
Eintrag öffnenCorlentor · 4.8 Undesirable effects · 1
Eintrag öffnenCorlentor · 4.8 · * Frequency calculated from clinical trials for adverse events detected from spontaneous report
Eintrag öffnenCorlentor · 4.8 · 8 The most common adverse reactions with ivabradine are luminous phenomena (phosphenes) (14.5%) and bradycardi
Eintrag öffnenCorlentor · 4.8 · 9 Rare* Malaise, possibly related to bradycardia
Eintrag öffnenCorlentor · 4.8 · Bradycardia was reported by 3.3% of patients particularly within the first 2 to 3 months of treatment initiati
Eintrag öffnenCorlentor · 4.8 · Description of selected adverse reactions
Eintrag öffnenCorlentor · 4.8 · In the SHIFT trial more patients experienced episodes of increased blood pressure while treated with ivabradin
Eintrag öffnenCorlentor · 4.8 · In the SIGNIFY study atrial fibrillation was observed in 5.3% of patients taking ivabradine compared to 3.8% i
Eintrag öffnenCorlentor · 4.8 · Luminous phenomena (phosphenes) were reported by 14.5% of patients, described as a transient enhanced brightne
Eintrag öffnenCorlentor · 4.8 · Reporting of suspected adverse reactions
Eintrag öffnenCorlentor · 4.8 · Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows con
Eintrag öffnenCorlentor · 4.8 · Summary of the safety profile
Eintrag öffnenCorlentor · 4.8 · System Organ Class Frequency Preferred Term Blood and lymphatic system Uncommon Eosinophilia disorders Metabol
Eintrag öffnenCorlentor · 4.8 · Tabulated list of adverse reactions
Eintrag öffnen